BioLife Solutions, Inc. (NASDAQ:BLFS) has been assigned a $6.00 price objective by equities researchers at Maxim Group in a research report issued on Friday. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Maxim Group’s target price suggests a potential upside of 57.89% from the stock’s previous close.
Separately, Janney Montgomery Scott raised shares of BioLife Solutions from a “neutral” rating to a “buy” rating and increased their price target for the company from $2.62 to $5.00 in a report on Wednesday, July 5th.
BioLife Solutions (BLFS) traded up 5.56% during midday trading on Friday, reaching $3.80. The company’s stock had a trading volume of 199,157 shares. BioLife Solutions has a one year low of $1.43 and a one year high of $3.95. The firm’s market cap is $49.54 million. The firm has a 50 day moving average price of $3.14 and a 200 day moving average price of $2.34.
BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 10th. The medical equipment provider reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06). BioLife Solutions had a negative net margin of 74.58% and a negative return on equity of 74.36%. The firm had revenue of $2.56 million during the quarter, compared to the consensus estimate of $2.40 million. Equities research analysts forecast that BioLife Solutions will post ($0.17) EPS for the current fiscal year.
WARNING: This news story was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/11/biolife-solutions-inc-nasdaqblfs-given-a-6-00-price-target-by-maxim-group-analysts.html.
BioLife Solutions Company Profile
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.
What are top analysts saying about BioLife Solutions Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioLife Solutions Inc. and related companies.